FDA Accepts Supplemental NDA for Sotyktu (Deucravacitinib) by Bristol
The FDA has accepted a supplemental NDA for Sotyktu (Deucravacitinib) submitted by Bristol.
Asset / Drug
Drug and asset intelligence for Bristol with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.